Sunitinib malate is under clinical development by Pfizer and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sunitinib malate LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sunitinib malate overview
Sunitinib malate (Sutent, SU011248) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Sunitinib malate is indicated for the treatment of gastrointestinal stromal tumors (GIST), advanced cholangiocarcinoma, renal cell carcinoma, islet cell carcinoma, pancreatic neuroendocrine tumor and metastatic renal cell carcinoma.
The drug candidate is under development for the treatment of renal cell carcinoma as an adjuvant therapy, refractory or progressive high grade glioma and ependymoma tumors, thymoma, thymic carcinoma, metastatic mucosal or acral lentiginous melanoma, cholangiocarcinoma, uveal melanoma, follicular thyroid cancer, papillary thyroid cancer, unresectable malignant pheochromocytoma, and paraganglioma. It was also under development for ependymoma, recurrent glioblastoma multiforme (GBM), high-grade glioma, HER2- breast cancer, HER-2 positive breast cancer, triple-negative breast cancer, metastatic hepatocellular carcinoma, metastatic breast cancer, non-small cell lung cancer, transitional cell carcinoma of bladder, small-cell lung cancer, anaplastic astrocytoma, prostate cancer, colorectal cancer, soft tissue sarcoma including liposarcoma, metastatic melanoma, leiomyosarcoma, pediatric GIST, fibrosarcoma, malignant fibrous histiocytoma, meningioma, meurofibromatoses type I and II, Von Hippel-Lindau syndrome and germ cell tumors as third line therapy.
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Sunitinib malate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
